Get the Stockscreener App
30.50
0.65%
-0.20
After Hours:
30.50
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $30.50, with a volume of 4.93M.
It is down -0.65% in the last 24 hours and down -1.55% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
See More
Previous Close:
$30.70
Open:
$30.36
24h Volume:
4.93M
Relative Volume:
1.14
Market Cap:
$15.65B
Revenue:
$11.89B
Net Income/Loss:
$-560.00M
P/E Ratio:
-27.73
EPS:
-1.1
Net Cash Flow:
$191.00M
1W Performance:
+1.26%
1M Performance:
-1.55%
6M Performance:
-9.52%
1Y Performance:
-8.76%
1-Day Range:
$29.93
$30.69
1-Week Range:
$29.93
$31.04
52-Week Range:
$26.25
$40.49
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(224) 948-2000
Address
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Resumed | Goldman | Buy |
| Feb-24-25 | Upgrade | Argus | Hold → Buy |
| Feb-20-25 | Resumed | Barclays | Overweight |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
California State Teachers Retirement System Sells 64,839 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
GF Fund Management CO. LTD. Buys Shares of 12,513 Baxter International Inc. (NYSE:BAX) - MarketBeat
Canada Clinical Nutrition Market Is Booming WorldwideBaxter, B. Braun Melsungen - openPR.com
Baxter International (BAX) Traded Higher Despite Tariff Disruptions - Insider Monkey
Public Employees Retirement System of Ohio Makes New Investment in Baxter International Inc. (NYSE:BAX) - MarketBeat
$3.94 Bn IV Hydration Therapy Markets - GlobeNewswire Inc.
Vitiligo Market Forecast and Competitive Landscape Report 2025-2033 Featuring Incyte, Bristol-Myers Squibb, Clinuvel Pharmaceuticals, Astellas, Baxter, Pfizer, and Dr. Reddy's LaboratoriesResearchAndMarkets.com - FinancialContent
IV Bag Market Is Booming WorldwideBaxter, B. Braun - openPR.com
BAXTER TO Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BAX Stock News - GuruFocus
Exclusive: Baxter CFO to Share Strategic Updates at Goldman Sachs Healthcare Conference - Stock Titan
Q3 EPS Forecast for Baxter International Cut by Analyst - MarketBeat
Do These 3 Checks Before Buying Baxter International Inc. (NYSE:BAX) For Its Upcoming Dividend - simplywall.st
We Wouldn't Be Too Quick To Buy Baxter International Inc. (NYSE:BAX) Before It Goes Ex-Dividend - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Raiffeisen Bank International AG Purchases Shares of 76,587 Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter launches room-temperature collagen sealing pad - MassDevice
Baxter launches HEMOPATCH Sealing Hemostat, a room-temperature collagen pad approved for Hemostasis and Sealing, suitable for open surgery and minimally invasive surgical procedures (MIS) - PR Newswire
Unpacking Q1 Earnings: Baxter (NYSE:BAX) In The Context Of Other Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Parkwood LLC Invests $10.75 Million in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. (NYSE:BAX) Receives Consensus Rating of “Hold” from Analysts - Defense World
Baxter’s Q4 Performance Beats Expectations - Medical Product Outsourcing
Baxter at Bank of America 2025 Healthcare Conference: Strategic Shifts and Growth - Investing.com Nigeria
Becton Dickinson Sues Baxter Over Infusion Pump Patents - Law360
BD files patent infringement lawsuit against Baxter over infusion pump tech - Drug Delivery Business
Becton Dickinson Says Baxter Infringes Infusion-Pump Patents - Bloomberg Law News
Transcript : Baxter International Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Hurricane Helene Updates - Baxter
Ameriprise Financial Inc. Sells 2,346,164 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Morgan Stanley Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter International Inc. (BAX) Announces Results of 2025 Annual Meeting - GuruFocus
Baxter International Holds 2025 Annual Meeting with Key Decisions - TipRanks
Baxter International Inc (BAX) Shares Up 4.23% on May 8 - GuruFocus
The 'Goldilocks' Case For Baxter International (NYSE:BAX) - Seeking Alpha
SHAREHOLDER ALERT: Potential Recovery for Baxter International Inc. (BAX) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Baxter International First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Baxter Interna - GuruFocus
Baxter International IncDeclares Quarterly Dividend Of $0.17 Per Share - marketscreener.com
Baxter Declares Quarterly Dividend | BAX Stock News - GuruFocus
Baxter Declares Quarterly Dividend - Bluefield Daily Telegraph
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL.com
What Are Wall Street Analysts' Target Price For Baxter International Stock? - Barchart.com
What Are Wall Street Analysts' Target Price for Baxter International Stock? - inkl
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Vera Therapeutics (VERA) - The Globe and Mail
Wells Fargo & Company Issues Pessimistic Forecast for Baxter International (NYSE:BAX) Stock Price - Defense World
Baxter stock rises on earnings beat, guidance raise - MSN
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):